| name | endo-hsd-t-trial |
| description | Suggests a 3- to 6‑month trial of testosterone dosing to achieve a mid‑normal premenopausal value in a reference assay for postmenopausal women with properly diagnosed HSDD and no contraindications. Triggered when a postmenopausal woman requests therapy for low sexual desire after appropriate HSDD workup and exclusion of contraindications. |
Suggest a testosterone trial for diagnosed HSDD
STEP 1 — Gather Information
Confirm postmenopausal status, diagnose HSDD per DSM‑5 after ruling out medical, psychiatric, and relationship causes, obtain baseline total testosterone (or free testosterone) using a validated assay, and screen for contraindications (androgen‑sensitive malignancy, uncontrolled hyperandrogenism, pregnancy, breastfeeding, significant liver disease).
STEP 2 — Rule In / Rule Out
Is the patient a postmenopausal woman with a confirmed HSDD diagnosis and no contraindications to testosterone? If yes, proceed to Step 3; if no, do not initiate a testosterone trial and address underlying causes or consider alternative therapies.
STEP 3 — Classify or Stratify
Compare baseline testosterone to the mid‑normal premenopausal reference range (e.g., 20‑30 ng/dL total T). If baseline is below this range, the patient is a candidate for a testosterone trial; if baseline is within or above the range, consider non‑hormonal approaches or avoid testosterone to prevent excess.
STEP 4 — Decide
Initiate a 3‑ to 6‑month trial of a non‑oral testosterone preparation (e.g., transdermal patch delivering ~300 µg/day, gel, or cream) titrated to achieve a mid‑normal premenopausal level; schedule follow‑up at 3–6 weeks to assess symptoms, side effects, and testosterone level, then every 3 months thereafter, and discontinue after 6 months if no meaningful improvement in sexual desire.
Clinical Guardrails / Mimics / Pitfalls
Monitor for signs of androgen excess (acne, hirsutism, voice deepening, clitoromegaly); avoid oral testosterone or DHEA formulations due to variable dosing and safety data; do not exceed physiological dosing that yields supraphysiological levels; avoid use in women with history of breast or endometrial cancer, uncontrolled liver disease, or pregnancy; reassess need for continued therapy at 6 months and stop if ineffective.
Concrete Clinical Example
A 58‑year‑old postmenopausal woman reports 6 months of distressing low sexual desire; HSDD is confirmed after negative depression screen, normal thyroid, and stable relationship; baseline total testosterone is 12 ng/dL (below mid‑normal premenopausal ~25 ng/dL); she has no contraindications. She starts a transdermal testosterone patch 300 µg/day. At 4‑week visit she reports improved desire and no androgenic signs; therapy is continued for up to 6 months with periodic testosterone checks, then stopped if no further benefit.
Source: Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2260
